Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CytRx Corporation (CYTR)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1437+0.0137 (+10.54%)
At close: 03:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1300
Open0.1300
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's Range0.1300 - 0.1550
52 Week Range0.0900 - 4.7000
Volume106,671
Avg. Volume190,145
Market Cap6.249M
Beta (5Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)-0.3550
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYTR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CYTRX CORP
    Daily – Vickers Top Buyers & Sellers for 05/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Business Wire

    CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

    LOS ANGELES, May 19, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 pm Eastern Time on May 20, 2022. The outstanding shares of

  • Business Wire

    CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

    LOS ANGELES, May 17, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. ("KemPharm").

  • Business Wire

    CytRx Partners with Oncology Development Expert to Advance LADR Platform

    LOS ANGELES, April 20, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered with oncology development expert Gilad Gordon, MD to assist the Company in developing its next-generation LADR drugs toward first-in-human clinical trials.

Advertisement
Advertisement